The MissilEX® Intracranial Thrombectomy Stent System, supported by CCRC Medtech’s full-cycle clinical trial services, has recently received marketing authorization from China’s National Medical Products Administration (NMPA). This milestone not only represents a major advancement in neurointervention but also redefines treatment paradigms for acute ischemic stroke (AIS), demonstrating CCRC Medtech’s technical expertise in high-risk medical device CRO services. End-to-End CRO Services Accelerate Innovative Product Commercialization Throughout the development and approval process of MissilEX®, CCRC Medtech provided full-cycle clinical trial services that proved instrumental in accelerating the product’s path to market. The company’s team demonstrated exceptional professionalism in clinical trial design, efficient multicenter project management, and rigorous data analysis. Facing the complexities inherent in clinical trials for high-risk devices like thrombectomy stents, CCRC Medtech

On July 25, the inaugural member conference and innovation salon of the Baoshan District Biopharmaceutical Industry Association was successfully held in Shanghai. As a key platform integrating biopharmaceutical resources and fostering industry-academia collaboration in Baoshan District, the event brought together leading biopharmaceutical companies, research institutions, investment firms, and government representatives to discuss “industry innovation breakthroughs and global development.” At the conference, Julia Yuan, General Manager of CCRC Medtech, was specially invited by the Baoshan District Science and Technology Commission to deliver a keynote speech titled “Empowering Device Innovation for Global Expansion.” Drawing on industry experience and global perspectives, she provided an in-depth analysis of the opportunities and challenges Chinese medical device companies face in international markets, offering forward-thinking and practical

March 2025 – A landmark study validating the Analytics for Life (A4L) non-invasive coronary artery disease (CAD) detection system for mainland Chinese populations was published in Discover Medicine by Professor Qian Juying’s team at Zhongshan Hospital, Fudan University. As the core clinical research partner for this Sino-US collaborative project, CCRC Medtech provided pivotal support in cross-population efficacy validation through its end-to-end clinical capabilities and medical-engineering integration expertise. 625-Patient Single-Center Study Demonstrates Clinical Research Excellence CCRC Medtech executed this prospective, single-center study at Zhongshan Hospital with 625 enrolled subjects, ensuring scientific rigor through: Strict adherence to U.S. study inclusion/exclusion criteria for cross-population data comparability Precision screening of signal quality/outliers, yielding 458 valid samples (including 348 significant CAD patients) Bias-free analysis pairing A4L results with invasive coronary angiography (ICA), safeguarding conclusions Benchmarking Medical-Engineering Collaboration CCRC Medtech’s leadership in medical device translation stems from its multidisciplinary synergy and globally recognized study experience, including: Cardiovascular

Strasbourg, France – As the Society of Robotic Surgery (SRS) 2025 Annual Meeting enters its core agenda phase, Julia Yuan, General Manager of CCRC Medtech, has emerged as the sole regulatory authority from Greater China, captivating global attendees with her deep expertise. After concluding three pivotal discussions on July 16, she is now poised to lead the Telesurgery Closed-Door Summit on July 19—an exclusive gathering of the world’s top surgeons, regulators, and industry leaders to harmonize global remote surgery standards. Decoding Greater China’s Market Dynamics & Regulatory Landscape During Plenary Session 2: Medical Device Regulation, Julia Yuan delivered high-impact analyses on regional regulatory frameworks, spotlighting: Market Position: With its vast population, growing healthcare demands, and innovation-friendly policies, Greater China is now the world’s second-largest medical device market. The surgical robotics sector, after years of development,

In the first half of 2025, China’s National Medical Products Administration (NMPA) intensified technical guidance for innovative medical device development and registration, resulting in 45 approved innovative medical devices—an 87.5% year-on-year increase. This surge reflects China’s booming medtech innovation landscape, powered in part by specialized CROs like CCRC Medtech, which facilitated 5 high-impact approvals in neurointervention, cardiovascular intervention, and pulsed-field ablation—fields with urgent clinical needs and high technical barriers. CCRC-Medtech-Empowered Innovative Devices (H1 2025) Peripheral Venous Thrombectomy Stent System (Import Registration No.: 20253030131) Flow-Diverting Stent (Domestic Registration No.: 20253130732) Cardiac Pulsed-Field Ablation System & Disposable Ablation Catheter (Domestic Registration Nos.: 20253010860 & 20253010879) Pulmonary Artery Thrombectomy System (Import Registration No.: 20253030265)   Full-Lifecycle CRO Services: The “Innovation Accelerator” As a strategic partner in medtech translation, CCRC Medtech integrates technical empowerment, process

July 1, 2025 – CCRC Medtech has officially relocated its Beijing office to Dongjin International Center, east of Yaowahu Bridge in Chaoyang District, marking a strategic upgrade in both workspace and service capabilities. Since its establishment in 2017, the Beijing office has served over 100 regional clients, and this move signifies CCRC Medtech’s entry into a new phase of refined and efficient clinical research services for medical devices in North China. From Regional Hub to Industry Nexus The new location in Chaoyang District’s Eastern Fourth Ring Road business belt—part of Beijing’s Eastern Science and Technology Corridor—offers proximity to key medical device industry clusters within a 30-minute commute. Surrounded by top-tier hospitals and CBD resources, the office strengthens CCRC Medtech’s end-to-end service ecosystem (clinical research, regulatory submissions, and global collaboration),